Pharmaceutical Executive March 25, 2024
The FDA granted accelerated approval to Elahere in November 2022 for patients with FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who were previously administered one to three systemic treatment regimens.
The FDA has granted a full approval to Elahere (mirvetuximab soravtansine-gynx) for adults with FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who were previously administered one to three systemic treatment regimens.1 The FDA granted accelerated approval to Elahere in November 2022 for this indication.2
Manufacturer ImmunoGen, Inc. was then acquired by AbbVie in November 2023 along with its flagship antibody drug conjugate (ADC) Elahere.3
“The full FDA approval of Elahere for eligible patients with ovarian cancer represents the culmination of years of work by...
Today's Sponsors
Today's Sponsor